Labcorp is Scheduled to Speak at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference
February 23 2021 - 6:54AM
Business Wire
Labcorp (NYSE: LH), a leading global life sciences company,
today announced that members of the executive management team will
participate in a virtual fireside chat at Citi's 2021 Healthcare
Services, Medtech, Tools, & HCIT Virtual Conference on
Thursday, Feb. 25 at 1:30 p.m. ET.
A live webcast of the presentation will be available via the
company website at www.Labcorp.com and archived for replay.
About Labcorp
Labcorp is a leading global life sciences company that provides
vital information to help doctors, hospitals, pharmaceutical
companies, researchers, and patients make clear and confident
decisions. Through our unparalleled diagnostics and drug
development capabilities, we provide insights and accelerate
innovations to improve health and improve lives. With more than
75,000 employees, we serve clients in more than 100 countries.
Labcorp (NYSE: LH) reported revenue of $14 billion in FY2020. Learn
more about us at www.Labcorp.com or follow us on LinkedIn and
Twitter @Labcorp.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements,
including, but not limited to, statements with respect to the
estimated 2021 guidance and the related assumptions, the impact of
various factors on operating and financial results, including the
projected impact of the COVID-19 pandemic on the company’s
businesses, operating results, cash flows and/or financial
condition, statements relating to our responses to and the expected
future impacts of the COVID-19 pandemic, on our business more
generally as well as on general economic, business, and market
conditions, future business strategies, expected savings and
synergies (including from the LaunchPad initiative and from
acquisitions), and the opportunities for future growth.
Each of the forward-looking statements is subject to change
based on various important factors, many of which are beyond the
company’s control, including without limitation, the impact of the
COVID-19 pandemic and its impact on our business and financial
condition and on general economic, business, and market conditions,
our ability (or inability) to execute on our plans to respond to
the COVID-19 pandemic, competitive actions and other unforeseen
changes and general uncertainties in the marketplace, changes in
government regulations, including healthcare reform, customer
purchasing decisions, including changes in payer regulations or
policies, other adverse actions of governmental and third-party
payers, changes in testing guidelines or recommendations, federal,
state, and local government responses to the COVID-19 pandemic, the
effect of public opinion on the company’s reputation, adverse
results in material litigation matters, the impact of changes in
tax laws and regulations, failure to maintain or develop customer
relationships, our ability to develop or acquire new products and
adapt to technological changes, failure in information technology,
systems or data security, adverse weather conditions, the number of
revenue days in a financial period, employee relations, personnel
costs, and the effect of exchange rate fluctuations. These factors,
in some cases, have affected and in the future (together with other
factors) could affect the company’s ability to implement the
company’s business strategy and actual results could differ
materially from those suggested by these forward-looking
statements. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.
The company has no obligation to provide any updates to these
forward-looking statements even if its expectations change. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement. Further information on
potential factors, risks and uncertainties that could affect
operating and financial results is included in the company’s most
recent Annual Report on Form 10-K and subsequent Forms 10-Q,
including in each case under the heading RISK FACTORS, and in the
company’s other filings with the SEC. The information in this press
release should be read in conjunction with a review of the
company’s filings with the SEC including the information in the
company’s most recent Annual Report on Form 10-K, and subsequent
Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
###
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210223005625/en/
Labcorp Contacts: Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com
Media: Christopher
Allman-Bradshaw — 336-436-8263 Media@Labcorp.com
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2023 to Apr 2024